Foghorn Therapeutics Inc.
NASDAQ:FHTXBiotechnology
+$0.10 today
- Market cap
- $109.73M
- Beta
- 2.89
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$1.08
Volume 1.76M
Average 0.15M
FHTX EBITDA Margin
EBITDA as a percentage of revenue.
Foghorn Therapeutics Inc.NASDAQ: FHTX
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to -601.1%
EBITDA Margin was -601.1% in Q1 FY2026, down 298.5 pp from a year earlier. On a trailing-twelve-month basis it was -257.0%, up 77.3 pp year over year. Over 3 fiscal years it widened by 319.4 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 4 analysts of -20.8% for the fiscal year ending Dec 2026, up from -229.5% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -601.1%-375.5 pp QoQ
- Last fiscal yearDec 2025
- -229.5%+200.3 pp YoY
- LTMMar 2026
- -257.0%+77.3 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -229.5%
- Year-over-year change
- +200.3pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -229.5% | +200.3pp |
| FY2024 | 2024-12-31 | -429.9% | -164.2pp |
| FY2023 | 2023-12-31 | -265.7% | +283.3pp |
| FY2022 | 2022-12-31 | -549.0% | +6743.4pp |
| FY2021 | 2021-12-31 | -7292.4% | — |
EBITDA Margin vs competitors
How FHTX compares with its peers on the latest reported figures
- FHTX's LTM Mar 2026 EBITDA Margin of -257.0% is the 5th highest of the 8 companies compared; the peer median is -148.9%.
- Its year-over-year change of +77.3 pp is the 2nd highest of 7, against a peer median of -70.8 pp.
- Over three fiscal years its change of +319.4 pp compares with a peer median of -82.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -8.8% | +113.4 pp | — | |
| LTM Mar 2026 | -62.6% | -41.0 pp | -64.2 pp | |
| LTM Mar 2026 | -67.3% | +67.9 pp | +30.0 pp | |
| LTM Mar 2026 | -148.9% | -100.7 pp | -100.7 pp | |
| LTM Mar 2026 | -257.0% | +77.3 pp | +319.4 pp | |
| LTM Mar 2026 | -547.9% | — | — | |
| LTM Mar 2026 | -2873.3% | -2889.4 pp | — | |
| LTM Mar 2026 | -3956.7% | -3182.9 pp | -1247.4 pp | |
SGMTSagimet Biosciences Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
ZURAZura Bio Limited | FY2025 | — | — | — |
| Peer median (excluding FHTX) | -148.9% | -70.8 pp | -82.4 pp | |
Competitors are the stored peer set for FHTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.32M | 19.23M | 34.16M | 22.6M | 30.91M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 3.33M |
| Gross Profit | 1.32M | 19.23M | 34.16M | 22.6M | 27.58M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 89.2% |
| Research & Development | 80.33M | 105.62M | 109.69M | 94.53M | 85.47M |
| Selling, General & Admin | 21.73M | 30.75M | 32.37M | 28.36M | 27.55M |
| Operating Expenses | 102.05M | 136.37M | 142.06M | 125.29M | 109.68M |
| Depreciation & Amortization | 3.23M | 3.32M | 3.45M | 3.12M | 3.33M |
| EBITDA | (96.19M) | (105.56M) | (90.75M) | (97.17M) | (70.95M) |
| EBITDA Margin | -7292.4% | -549.0% | -265.7% | -429.9% | -229.5% |
| Operating Income | (100.73M) | (117.14M) | (107.91M) | (102.68M) | (82.11M) |
| Operating Margin | -7637.1% | -609.2% | -315.9% | -454.3% | -265.6% |
| Interest Income | 59K | 5.68M | 10.88M | 11.9M | 8.75M |
| Interest Expense | 1.91M | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (586K) | 8.26M | 13.71M | 16.06M | 7.82M |
| Income Before Tax | (101.32M) | (108.88M) | (94.2M) | (86.62M) | (74.28M) |
| Pre-Tax Margin | -7681.6% | -566.3% | -275.8% | -383.2% | -240.3% |
| Income Tax Expense | 0 | 0 | 4.23M | 0 | 0 |
| Net Income | (101.32M) | (108.88M) | (98.43M) | (86.62M) | (74.28M) |
| Net Margin | -7681.6% | -566.3% | -288.2% | -383.2% | -240.3% |
| EPS (Basic) | (2.78) | (2.62) | (2.34) | (1.58) | (1.18) |
| EPS (Diluted) | (2.78) | (2.62) | (2.34) | (1.58) | (1.18) |
| Weighted Avg Shares | 37.17M | 41.59M | 41.97M | 54.9M | 62.98M |
| Weighted Avg Shares (Diluted) | 37.17M | 41.59M | 41.97M | 54.9M | 62.98M |
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Intrinsic Alpha fair value
Locked
Current Price
$1.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.